- Home
- ALT
ALT
Altimmune Inc.
as 07-26-2024 4:00pm EST
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 469.4M | IPO Year: | N/A |
| Target Price: | $18.80 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.09 - $14.84 | Next Earning Date: | 08-08-2024 |
| Revenue: | $410,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -99.21% | Revenue Growth (next year): | N/A |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
GlobeNewswire
25 days ago
Altimmune to Participate at Leerink Partners Therapeutics Forum
GlobeNewswire
a month ago
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
Yahoo Finance Video
a month ago
Crypto under pressure, Good Buy or Goodbye: Market Domination
Yahoo Finance Video
a month ago
Altimmune reports positive results in weight-loss drug trial
GlobeNewswire
a month ago
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
GlobeNewswire
a month ago
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
Simply Wall St.
a month ago
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.